Introduced
by
To prohibit makers and sellers of prescription drugs from offering an inducement to doctors to prescribe a drug, and impose an extensive new reporting mandate on the companies’ marketing programs.
Referred to the Committee on Health Policy
Reported without amendment
Refer to the Committee on Ways and Means with the recommendation that the substitute (H-1) be adopted.
Referred to the Committee on Ways and Means
